BMY—Breyanzi shows phase-3 statsig-superior EFS compared to SoC (high-dose chemo followed by stem-cell transplant) in second-line, large B-cell lymphoma: https://www.businesswire.com/news/home/20210610005259/en Bryanzi’s existing label includes only the third-line setting (#msg-161552697).